OSI-906 and Irinotecan in Patients With Advanced Cancer
Status:
Terminated
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This study plans to learn more about an investigational drug called OSI-906. OSI-906 is being
looked at to see if it could be a treatment for advanced cancer. "The FDA is the U.S.
government agency that reviews the results of research of drugs and decides if it can be sold
in the U.S. OSI-906 has been given to over 185 people with cancer.